Oct. 1, 2020—Specific regions of the thalamus — a central brain region — are smaller in adults with psychotic disorders and youth at risk for psychotic disorders and are associated with cognitive impairment.
Jun. 23, 2020—The insula, a small region of the brain involved in diverse brain functions had widespread dysconnectivity in schizophrenia, Vanderbilt researchers found.
Sep. 10, 2019—Studies of relational memory function may reveal novel mechanisms for therapeutic intervention for patients in the early stages of psychosis.
Jul. 11, 2019—Functional MRI studies have revealed that targeting activation of certain brain regions may improve working memory and cognition in psychotic disorders.
Jun. 24, 2019—Inhibited temperament—a tendency to respond to novelty with wariness, fear or caution—may be a risk factor for schizophrenia that could be targeted for preventative interventions.
Jan. 14, 2019—Psychiatrists diagnose people with schizophrenia, ADHD, bipolar disorder and other mental illnesses by spending time with them, looking for the particular behavior symptoms of each. What follows can be a hit-or-miss series of medications and dosages until disruptive behaviors go away. By deciphering the circuitry of the medial frontal cortex – an area beneath the...
Dec. 21, 2018—Vanderbilt University researchers are working to understand how people with schizophrenia experience emotion through their bodies.
Jun. 14, 2018—Symptoms of schizophrenia and bipolar disorder, including psychosis, depression and manic behavior, have both shared and distinguishing genetic factors, an international consortium led by researchers from Vanderbilt University and Virginia Commonwealth University is reporting.
Mar. 9, 2018—Brain imaging studies have implicated the connection between two brain regions in the pathophysiology of schizophrenia.
Jan. 8, 2018—Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.
Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.
Dec. 27, 2016—Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.